tbuckley/cabot-search huggingface dataset:
P227 Study of clinical characteristics of patients with vocal cord dysfunction
Authors: N Pargeter, AH Mansur
Journal: Thorax (2016)

<h3>Introduction</h3> Vocal Cord Dysfunction (VCD) is a poorly understood condition. It co-exists with and mimics asthma resulting in misdiagnosis and treatment of both conditions.<sup>1</sup> To better understand this population we established a VCD registry of referrals to our VCD centre extending over a 10 year period. <h3>Method</h3> The data recorded in the registry include patient demographics, symptoms, triggers, concomitant conditions and quality of life measures. Patients were asked to complete a questionnaire of symptoms/triggers and lung function tests were conducted. <h3>Results</h3> Over a period of 10 years there were 476 consecutive referrals to our service with probable VCD diagnosis. N = 249 (52%) had nasendoscopy-confirmed VCD diagnosis and adequate clinical details. <b><i>Demographics –</i></b> The majority of referrals were from the severe asthma clinic (150/249, 60%), Female: Male = 200:49, mean age 45 years (range 14–77), BMI Mean: 30.9kg/m<sup>2</sup>, range: 21–67. <b><i>Concomitant conditions</i></b>: Gastro-oesophageal reflux 172 (69%); Globus pharyngeus 136 (55%); Rhinitis 92 (37%); Asthma 203 (82%). Spirometry: Mean actual FEV1: 2.23L (SD ± 0.86), mean FEV1% pred: 87.91 (SD ± 26.6), mean FEV1/FVC ratio = 74.5 (SD ± 13.0). Psychological status - Hospital anxiety and depression score: Anxiety: mean 11 (range 2–21); depression: mean 8 (range 0–18). The clinical features of this population are provided in the table below. <h3>Conclusions</h3> Patients with VCD present with a definable range of triggers and symptoms and suffer from disabling and frequent comorbidities including psychological disease which clinicians need to be aware of when managing the condition. Further work is required to define the disease natural history and long-term outcomes through establishment of a properly designed UK wide VCD registry. <h3>Reference</h3> Ayres JG, Mansur AH. Vocal cord dysfunction and severe asthma. <i>American Journal of Respiratory and Critical Care Medicine</i> 2011;<b>184</b>(1):2–3.
MA07.01 Updated Pooled Analysis of CNS Endpoints in Two Phase II Studies of Alectinib in ALK+ NSCLC
Authors: Sai-Hong Ignatius Ou, Leena Gandhi, Alice Shaw, Ramaswamy Govindan, Mark Socinski, D. Ross Camidge, Luigi De Petris, Dong-Wan Kim, Alberto Chiappori, Denis Moro-Sibilot, Michaël Duruisseaux, Lucio Crinò, Tommaso De Pas, Eric Dansin, Antje Tessmer, James Chih-Hsin Yang, Ji-Youn Han, Walter Bordogna, Sophie Golding, Ali Zeaiter, Shirish Gadgeel
Journal: Journal of Thoracic Oncology (2017)
Abstract 14100: Marijuana (Cannabis) Use is an Independent Predictor of Stress Cardiomyopathy in Younger Men
Authors: Amitoj Singh, Sahil Agrawal, Mark Fegley, Yugandhar Manda, Sudip Nanda, Jamshid Shirani
Journal: Circulation (2016)

Background: Increased accessibility, recreational use and regional legalization of marijuana has been paralleled by widespread recognition of its serious cardiovascular complications (AMI, stroke, ...
P21 Pulmonary nodules: assessing the repeatability of imaging biomarkers of malignancy
Authors: A Talwar, JMY Willaime, LC Pickup, M Enescu, D Boukerroui, W Hickes, MJ Gooding, NM Rahman, T Kadir, FV Gleeson
Journal: Thorax (2016)

<h3>Introduction</h3> The BTS Pulmonary Nodule Guidelines recommend the use of nodule volumetry as a biomarker of malignancy in pulmonary nodules (PNs). Unfortunately, there is significant inter-scan volumetry measurement variability not representing true growth, of up to 25% (Gietema et al., 2007), with reliable growth detection requiring a scan time interval of up to 12 months. CT Texture analysis (CTTA) does not require volumetry detectable growth to detect change and may be a useful biomarker of malignancy. <h3>Aims and objectives</h3> To assess the repeatability of texture features extracted from PNs and compare this to the inter-scan variability of volume measurements. <h3>Materials and methods</h3> 40 patients, (20 with an indeterminate PN and 20 with pulmonary metastases) underwent two Low Dose Volumetric CT scans within a 60 minute period. 20 texture features previously used in combination to predict nodule probability of malignancy (BTS 2015) were extracted from each automatic contoured region surrounding the PN. The variability of texture measurements within individual nodules was assessed by computing the relative differences between baseline and validation scans. Mean and standard deviation (sd) were estimated from the relative differences. Lower and upper limits of repeatability (LLR and ULR) were calculated as mean ± 1.96 × sd. The intra-class correlation coefficient (ICC) was also used to assess the repeatability of the image features for this group of patients. <h3>Results</h3> Nodule volumes ranged from 76 to 8130 mm<sup>3</sup>, (mean 2D diameter 8.7 mm; sd 3.2) and were not statistically different between baseline and validation scans (p = 0.92, Wilcoxon rank sum test). The mean difference in volume between the two scans was 37.4 mm<sup>3</sup> (6.2%, sd 30.4). 18 out of 20 textural features displayed ULR and LLR below ± 26.2% (sd ≤ 12.3%). These were less variable than nodule volume (mean = 1.2%; sd = 14.4%; LLR = −27.0%; ULR = 29.5%). All features had high repeatability (0.87 ≤ ICC ≤ 0.99), see Figure 1. <h3>Conclusion</h3> The repeatability of CTTA was comparable to automatic volumetric measurements that are currently recommended for use in clinical practice. To our knowledge this is the first study to assess CTTA repeatability, a promising biomarker of malignancy.
Dynamic assessment of risk in clear cell renal cell carcinoma: The Emory Dynamic Model.
Authors: W. Harris, B. M. Lingerfelt, A. O. Osunkoya, V. A. Master
Journal: Journal of Clinical Oncology (2011)

e15123 Background: Kidney cancer is the most deadly of the common genitourinary malignancies. No biomarkers exist to guide therapy beyond the initial course of treatment. The purpose of this study was to develop a dynamic prognostic model for kidney cancer. Methods: Candidate biomarkers were identified from published prognostic models for clear cell renal cell carcinoma (ccRCC). Data quality for biomarker studies was assessed by REMARK guidelines. The biomarkers were classified as either static or dynamic with dynamic being defined as measurable in the circulation. Studies of dynamic biomarkers were reviewed to determine their impact on externally validated prognostic models. The most robust of the dynamic biomarkers were selected for inclusion in the Emory Dynamic Model (EDM). Results: Ten of the 20 dynamic biomarkers that were identified are acute phase reactants while the remaining 10 are commonly associated with inflammation. Of these, only C-reactive protein (CRP) has been included in an externally validated prognostic model, the TNM-C model. Serum amyloid A1 (SAA1) and CRP belong to the serum pentraxin (SP) family. Each has been shown to be an independent, adverse prognostic factor for ccRCC with a high degree of concordance. In the EDM, the SPs are viewed as atypical or “phenotypic” tumor markers. Patients are considered to be at high risk (HR) with an aggressive inflammatory phenotype (AIP) if pretreatment SP levels are elevated. When pretreatment SP levels are not elevated, patients are considered to be at low risk (LR) with a non-inflammatory phenotype (NIP). Simple algorithms further refine risk after therapeutic intervention including the perioperative CRP (pCRP) algorithm for localized disease and the Normalized CRP Period (NCP) algorithm for metastatic disease. Patients with persistent SP elevations after treatment are at extremely high risk (EHR) for rapid disease progression and death. Conclusions: The EDM is the first truly dynamic prognostic model for localized and metastatic ccRCC. With prospective validation, the EDM could become a useful tool for risk stratification in clinical trial design. Limitations include the need to extend follow up, refine SP cut-off levels and assess the NCP in localized disease.
TET2 Mutations in Polycythemia Vera (PV) in Some Cases Follow Rather Than Precede JAK2 V617F Mutation, Are Not a Disease-Initiating Event, Affect Mainly Erythropoiesis, and Contribute to Increased Aggressivity of PV Clone.
Authors: Sabina Swierczek, Christine Bellanne-Chantelot, Donghoon Yoon, Cecile Saint-Martin, Soo Jin Kim, Albert Najman, Josef T. Prchal
Journal: Blood (2009)
Prostaglandin E2 Is a Potent Regulator of Vertebrate Hematopoietic Stem Cell Homeostasis.
Authors: Trista E. North, Wolfram Goessling, Kamden R. Kopani, Claudia Lengerke, Carl R. Walkley, Allegra M. Lord, Il-ho Jang, Tilo Grosser, Garret A. FitzGerald, George Q. Daley, Stuart H. Orkin, Leonard I. Zon
Journal: Blood (2006)
OA15.07 Is Necessary Completion Lobectomy in NSCLC (≤ 2cm) with Visceral Pleural Invasion or Lymphovascular Invasion after Sublobar Resection?
Authors: Youngkyu Moon, Mi Hyoung Moon, Young Kyoon Kim, Kyo-Young Lee, Jae Kil Park, Sook Whan Sung
Journal: Journal of Thoracic Oncology (2017)
P196 Predicting escalation to intensive care for patients with pneumonia with a new clinical prediction rule: SNA³P
Authors: LE Hodgson, BD Dimitrov, C Stubbs, R Venn, LG Forni
Journal: Thorax (2016)

<h3>Introduction</h3> Many clinical prediction rules (CPRs) exist for community-acquired pneumonia (CAP), though few have been investigated to predict escalation to an intensive care unit (ICU). Furthermore, most include components (sometimes subjective) that do not allow the potential for electronic automation in clinical practice. <h3>Methods</h3> A historical cohort study was performed at two UK adult acute medical units (2013–15). Inclusion was based on an ICD-10 coded diagnosis of pneumonia. Primary outcome was escalation to ICU. Exclusion criteria was: direct ICU admission from A and E, a stay &lt;1 night, age &lt;18 or ≥80 or frail elderly, neutropenia, HIV, malignancy and palliative care. Predictive performance of CURB-65 was compared to CRB-65, CURB, the National Early Warning Score (NEWS) and a modified SMART-COP (SART-CO, as imaging and ABGs were not available) using receiver operating characteristics (ROC) analysis. Multivariable logistic regression was also performed to investigate additional predictors electronically available at admission (blood and physiological parameters). <h3>Results</h3> 1,305 of 24,706 medical admissions were included. 8.3% (n = 109) were escalated to ICU, with significantly increased in-patient mortality (31% vs 6.5%, p &lt; 0.001). 54% of ICU patients had, or developed, AKI vs 11% if not escalated (p &lt; 0.001). To predict escalation, AUCROCs for existing CPRs ranged from 0.54–0.61 (Figure). Using multivariable logistic regression a newly derived CPR – <b>SNA³P</b> - (including 6 components: <b>S</b>odium, <b>N</b>EWS ≥ 7, <b>A</b>lbumin, <b>A</b>ST, <b>A</b>KI and <b>P</b>latelets, score range 0–20 points) demonstrated a statistically significant increase in discrimination (AUCROC 0.80, 95% CI: 0.75–0.84). At a cut-off of 2 points to predict ICU escalation, sensitivity was 92% (95% CI: 85–96%), specificity 48% (45–51), positive predictive value (PPV) 14% (11–16) and negative predictive value 98% (97–99); at 6 points sensitivity was 53% (43–63), specificity 87% (85–89), PPV 27% (21–33) and NPV 95% (94–96). <h3>Conclusion</h3> Existing pneumonia CPRs, largely derived to predict mortality, have shortcomings when predicting those who require escalation to ICU. The newly derived rule <b>SNA³P</b>, if externally validated could be incorporated into an electronic clinical decision support system to provide automatic objective assessment and evidence of risk at point-of-care for those who may be considered for escalation.
The Combination of AMD3100 + G-CSF Restores the Ineffective Hematopoietic Stem Cell Mobilization with G-CSF Alone in a Thalassemic Mouse Model.
Authors: Evangelia Yannaki, Nikoleta Psatha, Maria Demertzi, Evangelia Athanasiou, Eleni Sgouramali, Dimitris Bougiouklis, Minas Arsenakis, Achilles Anagnostopoulos, Athanasios Fassas
Journal: Blood (2009)
Recovery of Thymic Epithelial Cells and T Cell Immune Reconstitution After Cord Blood Transplantation in Adults Depends On Angiogenesis and Neovascularization
Authors: Ioannis Politikos, Haesook Kim, Julia Brown, Sean McDonough, Lequn Li, Corey Cutler, Joseph H. Antin, Karen K. Ballen, Jerome Ritz, Vassiliki A. Boussiotis
Journal: Blood (2012)
A Dose Finding Lead-in Study of E7777 (Diphtheria toxin fragment-Interleukin-2 Fusion Protein) in Persistent or Recurrent Cutaneous T-Cell Lymphoma (CTCL)
Authors: Madeleine Duvic, Timothy M Kuzel, Nam H. Dang, Miles Prince, Tatyana Feldman, Francine M. Foss, Matthew Guo, Lone Harild Ottesen, Chean Eng Ooi, Youn H Kim
Journal: Blood (2014)
P3.02c-087 The Relationship of TILs and PD-L1 Expression in NSCLC Adenocarcinoma in Little to Non-Smokers with Driver Mutations and Outcome Parameters
Authors: Sacha Mignon, Karen Willard-Gallo, Gert Van Den Eynden, Roberto Salgado, Wim Waelput, Lore Decoster, Koen Mariën, Johan Vansteenkiste, Erik Teugels, Jacques De Grève
Journal: Journal of Thoracic Oncology (2017)
Impaired ristocetin–induced Platelet Aggregation in Whole Blood Assessed with a Multiplate© Analyser Suggests a New Mechanism of Antiplatelet Effect of Aspirin and Clopidogrel,
Authors: Annick Ankri, Anne Baranger, Isabelle Martin-Toutain, Yves Samson, Jean-Philippe Collet, Gilles Montalescot, Lise Lejean
Journal: Blood (2011)
Higher Prevalence But Similar Infectious Profile Overtime After Haploidentical Transplantation Compared With HLA-Identical Transplantation For Hematological Diseases
Authors: Roberto Crocchiolo, Luca Castagna, Andrea Vai, Barbara Sarina, Stefania Bramanti, Elisa Mauro, Carmelo Carlo-Stella, Armando Santoro
Journal: Blood (2013)
P1.07-048 Clinical Impact of the Relationship between Post-Progression Survival and Overall Survival in Extensive Disease Small Cell Lung Cancer Patients
Authors: Hisao Imai, Keita Mori, Nodoka Watase, Sakae Fujimoto, Kyoichi Kaira, Masanobu Yamada, Koichi Minato
Journal: Journal of Thoracic Oncology (2017)
The role of adjuvant chemotherapy in early-stage high-grade uterine leiomyosarcoma: A retrospective review.
Authors: M. Klobocista, A. A. Yessaian, C. P. Morrow, L. Muderspach, H. Pham, Y. G. Lin, R. Sposto, L. Roman
Journal: Journal of Clinical Oncology (2011)

e15500 Background: Although the majority of patients with uterine leiomyosarcoma (ULMS) present with early stage disease, the risk of recurrence is high. Because ULMS is a rare disease, standardized adjuvant treatment options do not exist. Therefore, the goal of this study is to determine the role of adjuvant chemotherapy in patients with stages I-II high grade ULMS. Methods: Women with stages I-II ULMS treated at our institution from 1988-2008 were retrospectively identified and included in this study (N=44). Data was collected on patient age, stage of disease, surgical procedure, adjuvant treatment, recurrence, and survival. Results: In this population, 24 (55%) patients received cytotoxic chemotherapy, 3 (7%) received concurrent chemoradiation, 2 (4.5%) patients received radiation alone, and 15 (34%) received no further treatment. Median follow up for survivors was 71 months. In the no treatment and radiation alone groups, 71% of patients recurred and 29% were alive at last follow up. In the chemotherapy and chemoradiation groups, 63% of patients recurred and 48% were alive at last follow-up. There was also a difference noted based on type of chemotherapy received. Patients who received adriamycin and ifosfamide had a recurrence rate of 25%, and 63% were alive at last follow up. In the gemcitabine and docetaxel group, while 75% of these patients recurred, many of these recurrences were salvageable, thus 75% of patients were alive at last follow up. The five year survival rate for patients who received chemotherapy was 58% compared to 48% for those who did not receive chemotherapy (p=0.09). The five year survival rate for patients who received combination chemotherapy was 91% compared to 39% for patients who received single agent chemotherapy (p=0.07). Conclusions: Adjuvant chemotherapy, especially combination chemotherapy for early stage high grade ULMS in this series demonstrates a benefit and even a trend towards improved outcome.
P152 Inhaled corticosteroid (ICS) and long acting beta-adrenoceptor agonist (LABA) therapy adherence reporting and monitoring in clinical trials of severe adult asthma drug treatments: a systematic review
Authors: MC Mokoka, MJ McDonnell, B Cushen, S Cormican, I Sulaiman, F Doyle, F Boland, RW Costello
Journal: Thorax (2016)

<h3>Background</h3> Assessment of adherence to inhaled corticosteroids and long-acting beta-agonist therapy, allows identification of patients classified as having refractory asthma. It is crucial to ensure that adherence is adequately assessed in clinical practice and in the conduct of clinical trials to target the patients who may benefit from expensive potential add-on therapies. We hypothesised that adherence to inhaled corticosteroids and long acting β<sub>2</sub>-agonists is under-assessed and under-reported in clinical trials of add-on drug treatment interventions in adolescent and adult patients with severe asthma. <h3>Methods</h3> A systematic literature search of six major databases was performed to identify randomised controlled trials (RCTs) of asthma drug treatment interventions conducted in severe adolescent and adult asthma patients taking inhaled corticosteroids (ICS) alone or in combination with long-acting beta-agonist therapy (ICS/LABA). Identified studies were reviewed concerning key characteristics of the trial and the intervention; reporting and monitoring of adherence to ICS/LABA and the relationship between measuring adherence and study outcomes was assessed. This systematic review had been registered on PROSPERO; registration number CRD42015029611. <h3>Results</h3> The electronic search retrieved 5869 articles with an additional 19 identified from references. 4008 articles were screened after removal of duplicates of which 72 RCTs were included and underwent data extraction and quality scoring. Of these, only 12 RCTs reported adherence to ICS or ICS/LABA therapy. Measures of adherence used included; self-report, n = 1; self-report and inhaler technique, n = 1; inhaler technique, n = 1; inhaler technique and FeNO, n = 1; dose counting. n = 1; diary, n = 2; prescription records, n = 1; weighing inhaler canister, n = 1; assumption that primary respiratory physician had assessed adherence, n = 1; and method of adherence assessment not reported but measure of adherence included in n = 2 studies. High levels of heterogeneity across studies with regard to adherence and exacerbation measurements, designs and analysis precluded a formal meta-analysis. Although effect measures varied, good adherence was associated with fewer severe asthma exacerbations in high-quality studies. <h3>Conclusion</h3> Good adherence is associated with a lower risk of severe asthma exacerbations. Future studies should use standardised methodology to assess adherence and inhaler technique.
The role of collagen and COX-2 in post-partum breast involution on the progression of pregnancy-associated breast cancer and its inhibition by NSAIDs.
Authors: V. F. Borges, T. Lyons, J. O'Brien, T. Russell, H. Martinson, P. Keely, P. J. Schedin
Journal: Journal of Clinical Oncology (2011)

e11117 Background: Prognosis of young women’s breast cancer is influenced by reproductive history with worse prognosis when diagnosis is within five years postpartum. We propose that breast involution accounts for the poor prognosis of postpartum breast cancers (BC), as involution is identified by tissue remodeling programs that share similarities with tumor promoting microenvironments including elevated fibrillar collagen deposition and COX-2 expression. Methods: We developed murine models of postpartum BC. To determine if targeting COX-2 may decrease progression of postpartum BC, mice were treated with NSAID ibuprofen for two weeks during the window of involution. Further, the collagen/COX-2 pathway in human postpartum BC was investigated in breast tissue and DCIS from young women. Results: The normal murine involuting gland showed high levels of radiating collagen fibers organized similar to collagen from invasive tumors. Mammary tumors arising in this collagen-rich microenvironment have increased levels of COX-2. In vitro, tumor cells isolated from PABCs are motile and invasive in a collagen and COX-2 dependent manner. Surprisingly inhibition of COX-2 during involution decreased collagen levels and frequency of radial fibers. Ibuprofen treatment reduced tumor size, collagen architecture, COX-2 expression, and lung cell seeding. In humans, comparison of breast tissue from nulliparous women to involution shows increased levels of collagen and >2x the frequency of radially aligned fibers. In our DCIS study, analysis of COX-2 expression reveals a trend towards increased COX-2 expression in the postpartum DCIS lesions. Conclusions: Our results confirm involution as a driver of postpartum BC and indicate two roles for COX-2 in tumor cell invasion in the postpartum setting: 1) COX-2 activity in the tumor is required for motility and 2) COX-2 activity in the host promotes collagen fibrillogenesis, which promotes metastasis. The human correlative results implicate collagen and COX-2 in the poor prognosis of postpartum BC. Our data preliminarily support the idea of an NSAID intervention study for recently pregnant women at high risk for breast cancer.
P2.06-037 A Feasibility Study of Concurrent Chemoradiation Followed by Surgery for Pathologically-Proven Clinical IIIA-N2 Non-Small Cell Lung Cancer
Authors: Hiroyasu Yokomise, Fumihiro Tanaka, Toshinori Soejima, Hidetaka Uramoto, Takeharu Yamanaka, Nobuyuki Yamamoto, Kazuhiko Nakagawa, Yasumasa Nishimura, Hiroshi Niwa, Morihito Okada, Tatsuo Nakagawa, Motohiro Yamashita
Journal: Journal of Thoracic Oncology (2017)
MA07.05 EUCROSS: A European Phase II Trial of Crizotinib in Advanced Adenocarcinoma of the Lung Harboring ROS1 Rearrangements - Preliminary Results
Authors: Sebastian Michels, Masyar Gardizi, Petra Schmalz, Meike Thurat, Eva Pereira, Martin Sebastian, Enric Carcereny, Jesus Corral, Luis Paz-Ares, Enriqueta Felip, Christian Grohé, Delvys Rodriguez Abreu, Amelia Insa Molla, Helge Bischoff, Martin Reck, Niki Karachaliou, Andreas Scheel, Vanessa Brandes, Fischer Rieke, Lucia Nogova, Matthias Scheffler, Jeremy Franklin, Martin Hellmich, Bartomeu Massuti, Reinhard Buettner, Rafael Rosell, Jürgen Wolf
Journal: Journal of Thoracic Oncology (2017)
Inhibition of Protein Kinase C beta by Enzastaurin (LY 317615) Induces Alterations of Key Regulators of Cell Cycle and Apoptosis in Mantle Cell Lymphoma and Synergizes with Chemotherapeutic Agents in a Sequence Dependent Manner.
Authors: Malte Rieken, Oliver Weigert, Alessandro Pastore, Grit Hutter, Yvonne Zimmermann, Marc Weinkauf, Wolfgang Hiddemann, Martin Dreyling
Journal: Blood (2005)